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modeling, event based microsimulation/patient level simulation. Health outcomes 
included survival, number-needed-to-treat, life expectancy, and quality-adjusted life 
years, time horizon and cycle length. All the studies were critically appraised using 
quality of health economic scale (QHES) and were found to be of moderate to high 
quality. Evaluated therapeutic strategies comprised chemotherapeutic combina-
tion therapies, stem cell transplantation and supportive care. ConClusions: Our 
review provides a comprehensive overview of modeling studies assessing treatment 
of DLBCL which could be used by researchers to develop novel models in DLBCL.
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objeCtives: Multiple-criteria decision analysis (MCDA) is a sub-discipline of opera-
tions research that explicitly considers multiple criteria in decision-making envi-
ronments. Formally structuring complex problems appropriately and considering 
multiple criteria explicitly leads to more informed and transparent decisions. MCDA 
methods are increasing in popularity, however existing instruments and approaches 
are rigid and do not reflect local decision making needs and preferences. ZRx MCDM 
was developed as a highly flexible tool to support the application of local multiple-
criteria decision analysis in health care. This tool was used to evaluate, as an example, 
three alternatives for the management of anemia associated with chronic kidney 
disease: Procrit, Aranesp and a Biosimliar (Epogen Zeta). Methods: There are mul-
tiple MCDA standard methods that can be applied and the ZRx MCDM tool has been 
validated against the publications of such methods. Users enter desirable data by 
selecting an appropriate number of alternatives and criteria relevant to particular 
decision-making context. Further, criteria scale and weights are defined to obtain 
results (alternatives in sequence of importance) per different MCDA calculation 
methods. Seven local decision-makers applied inter-criteria weights using visual 
analogue scale (VAS). Results: Applying the Simple Linear Adaptive Model (SLAM) 
method, the decision-making criteria as ranked in order of importance were safety, 
budget impact, cost-effectiveness and unmet medical need (equal third), patient 
preferences and strategic considerations. Global scores calculated for Aranesp were 
marginally higher than for the biosimilar (0.52 vs 0.51), whereas Procrit (0.46) scored 
lower. When Multi Attribute Value Theory (MAVT) method was further applied, total 
score differentiation was more pronounced: Aranesp, Biosimilar and Procrit (0.57, 0.50 
and 0.46). ConClusions: ZRx MCDM tool has been successfully applied in a local 
decision making context. By not relying on, or promoting, pre-defined criteria, level 
definitions and weighting/aggregation methods, the tool is fully flexible and adaptive 
to high precision local decision making needs and preferences.
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objeCtives: Several studies have considered the change in the price of medicines 
once a medicines patent expires and exclusivity in the market place is lost. Some 
HTA bodies consider the implications of patent expiry (e.g. PHARMAC) however the 
potential impact is not considered in the NICE reference case. The aim of this study 
was to consider how including the costs of medicines after patent expiry could impact 
cost-effectiveness results. Methods: A targeted review was conducted to identify 
any studies which had considered the impact of patent expiry. The approaches were 
compared and contrasted. A review of recent treatments that have received negative 
reimbursement decisions from HTA bodies were considered to determine if generic 
pricing could have influenced the decision making process. Results: Patent expiry 
has potential to impact results, however only in a handful of selected disease areas. 
The assumptions required to implement generic pricing after patent expiry can be 
associated with considerable uncertainty, particularly around the generic price of 
medicine. Further to this, the impact that generic pricing has is dependent on both 
duration of treatment and life expectancy of modelled populations. ConClusions: 
Patent expiry offers manufactures a chance to reduce the cost associated with treat-
ment without altering health outcomes. However this is likely to offer a comparable 
discount to a majority of comparators available in the market, therefore it is likely this 
will offer the biggest benefit to the manufactures that implement it first.
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objeCtives: To systematically review the existing applications of the early 
model-based techniques to innovative biomedical devices under development. 
Furthermore, our purpose is to identify their usefulness, limitations, potential 
improvements, impact on primary stakeholders and implications. Even though the 
early Health Technology Assessment (HTA) of new medical devices is recognized 
as an integral part of the technology production, many methodological criticali-
ties still afflict this field. The high level of uncertainty, connected with the scar-
city and heterogeneity of data, needs to be faced readjusting the mainstream HTA 
methodology to support both medical technology producers and policy makers 
alongside with the R&D process. Methods: Published studies in the English lan-
guage, related to period 2000-2015, were searched using computerized databases 
(Pubmed, Scopus, ScienceDirect, Web of Science, IEE Xplore) and reference search 
of the included articles. All papers that applied the health economic modeling to 
R&D medical devices met our inclusion criteria. Given the immaturity of the field, 
we also examined conference proceedings that met the same criteria. Results: 
good separation of all relevant components. This leads to models that are easy to 
formulate, validate, understand, maintain and update.
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objeCtives: Schizophrenia is a persistent and costly disease, which requires a 
continuous antipsychotic treatment. In antipsychotic treatment of schizophrenia, 
the differences in terms of effectiveness, tolerance, incidence of side effects, relapse 
and costs have implications regarding the cost-effectiveness. The objective of the 
specialistic research is to investigate the cost-effectiveness of two second generation 
antipsychotics (SGA) in treatment of patients with schizophrenia in the RS health-
care system. Methods: The Markov model was developed to assess the medical 
cost-effectiveness of olanzapine and risperidone (SGA) in relation to haloperidol 
(FGA) .The cohorts of patients were adult patients diagnosed with schizophrenia . 
Transitional probabilities were taken over from a major meta-analysis conducted 
by NICE. The cost considered in this model were taken over from list of rates Health 
insurance fund (HIF). The utility (in QALY) for remission or relapse were taken over 
from a scale published by Lenart et al. The cost-effectiveness measure was the 
Incremental cost-utility ratio (ICUR) . The set threshold was 3200 EUR. Results: 
Undiscounted results of the basic cost-effectiveness analysis show ICUR for olan-
zapine= 912EUR/QALY, ICUR for risperidone = 1528 EUR/QALY. Discounted results 
show ICUR for olanzapine = 877EUR/QALY, ICUR for risperidone= 1502 EUR/QALY. 
Sensitivity analysis has shown , in case of increase in transition probability for 
relapse by 10%, olanzapine remains a cost-effective strategy, whereas risperidone 
becomes a cost-ineffective strategy. The sensitivity analysis has also shown the 
stability of the basic analysis results. ConClusions: No strategy showed itself as 
dominant, both alternative strategies having higher costs but also higher effective-
ness. The model showed that, it takes less money for a better quality in olanzapine 
than risperidone strategy, while in relation to the set threshold both strategies were 
cost-effective. Both olanzapine and risperidone have proven cost-effective strategies 
from the HIF perspective with the recommendation that olanzapine should also be 
included in the reimbursement list .
PRM116
ReviewinG The coST-eFFecTiveneSS oF cheMoTheRAPy And TARGeTed 
TheRAPy FoR MeTASTATic bReAST cAnceR
Pouwels XG, Ramaekers BL, Joore MA
Maastricht University Medical Center+, Maastricht, The Netherlands
objeCtives: To systematically review and assess the quality of model-based eco-
nomic evaluations concerning chemotherapy and targeted therapy for metastatic 
breast cancer (MBC). To analyse the impact of different modelling characteristics on 
the outcomes of these studies. Methods: The search was performed in PubMED and 
NHS EED. Inclusion criteria were: English or Dutch language, model-based economic 
evaluation, chemotherapy or targeted therapy as intervention, population diagnosed 
with MBC, published between 2000 and October 2014, reporting life-years (LY) or 
quality-adjusted life year (QALY), and reporting an incremental cost-effectiveness 
ratio (ICER). Quality of the studies was assessed through a checklist. A standardised 
extraction sheet was used to retrieve general characteristics, modelling character-
istics and results of the studies. Results: Twenty-six studies were included and 
provided fifty-two comparisons. Eighteen studies used a health state-transition model 
including the following health states: stable/progression-free disease, progression 
and death. Subgroup analyses were conducted in three studies. Studies were of poor 
quality. Administration frequency of the regimens, type of model, perspective of the 
analysis, elicitation method for utilities, total amount of QALY gained and funding 
source were not always reported. Incremental LY and incremental QALY (iQALY) var-
ied from 0.06 to 1.52 and from 0.05 to 0.60, respectively. Mean incremental cost was 
€ 18,977 (range: € -10,690 - € 84,174). Mean ICER per LY and per QALY gained were € 12,000 
(range: € 200 - € 64,000) and € 76,000 (range: € 300 - € 625,000), respectively. Seven com-
parisons were represented in two or three studies and were used to analyse the effect 
of modelling characteristics on the iQALY estimates. ConClusions: The results of 
the studies were highly variable and the quality of the studies was poor. Comparison 
of studies was hampered because of under-reporting and the limited number of stud-
ies comparing the same regimens. Consequently, no firm conclusions could be drawn 
concerning the effect of modelling characteristics on outcomes.
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objeCtives: Diffuse large B-cell lymphoma (DLBCL) is the most common form 
of NHL, accounting for up to 30 percent of newly diagnosed cases in the United 
States and Europe. The purpose of this study was to provide a clinician-friendly 
landscape of decision-analytic models evaluating different treatment strategies 
for DLBCL. Methods: A comprehensive search strategy was developed and a sys-
tematic literature search in Pubmed and EMBASE from 1996 to June 1, 2015 was 
queried to identify studies evaluating DLBCL treatment strategies using various 
decision-analytic models. Studies were screened using pre-defined inclusion criteria 
after which data from included trials were extracted, by two independent review-
ers and disagreements resolved by a third reviewer. We included studies that were 
published as full-text articles in English, and assessed relevant clinical endpoints, 
and summarized methodological characteristics (e.g., modeling approaches, simula-
tion techniques, health outcomes, perspectives). Results: Seven decision-analytic 
modeling studies met our inclusion criteria out of the total 289 citations. Major mod-
eling approaches adopted were: decision-tree modeling, Markov state-transition 
